Adma Biologics Inc Schwankungsanfälligkeit
Was ist das Schwankungsanfälligkeit von Adma Biologics Inc?
Schwankungsanfälligkeit von Adma Biologics Inc ist 4.49%
Was ist die Definition von Schwankungsanfälligkeit?
Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc
Was macht Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Unternehmen mit schwankungsanfälligkeit ähnlich Adma Biologics Inc
- Ventus VCT C hat Schwankungsanfälligkeit von 4.48%
- NeuroScientific Biopharmaceuticals hat Schwankungsanfälligkeit von 4.48%
- Zee Media hat Schwankungsanfälligkeit von 4.48%
- StarPower Semiconductor hat Schwankungsanfälligkeit von 4.48%
- Lords Chloro Alkali hat Schwankungsanfälligkeit von 4.48%
- Trigyn Technologies hat Schwankungsanfälligkeit von 4.48%
- Adma Biologics Inc hat Schwankungsanfälligkeit von 4.49%
- PDF Solutions hat Schwankungsanfälligkeit von 4.50%
- Enhabit hat Schwankungsanfälligkeit von 4.50%
- Avita Medical hat Schwankungsanfälligkeit von 4.50%
- Yanzhou Coal Mining Co hat Schwankungsanfälligkeit von 4.50%
- Goa Carbon hat Schwankungsanfälligkeit von 4.50%
- Rayonier Advanced Materials Inc hat Schwankungsanfälligkeit von 4.50%